POS-244 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE COMPARATOR CONVERSION STUDY OF ROXADUSTAT IN NON–DIALYSIS-DEPENDENT (NDD) PATIENTS WITH ANEMIA IN CHRONIC KIDNEY DISEASE (CKD)

Kidney International Reports, vol. 6, pp. S103

Abstract

Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in CKD. Efficacy and long-term safety of roxadustat was assessed, following conversion from darbepoetin alfa (DA), recombinant human erythropoietin (rHuEPO), or epoetin beta pegol (EBP) to roxadustat, in NDD-CKD patients (pts) with anemia. Non-inferiority of roxadustat efficacy against DA was evaluated.

Authors 4

1. Tadao Akizawa

   SHOWA Medical University

   Affiliation as printed

   Showa University School of Medicine, Nephrology, Tokyo, Japan

2. Manabu Iwasaki

   Yokohama City University

   Affiliation as printed

   Yokohama City University, Department of Data Science, Yokohama, Japan

3. T. Otsuka

   Astellas Pharma (Japan)

   Affiliation as printed

   Astellas Pharma- Inc., Japan-Asia Clinical Development, Tokyo, Japan

4. Yusuke Yamaguchi

   Astellas Pharma (Japan)

   Affiliation as printed

   Astellas Pharma- Inc., Japan-Asia Data Science, Tokyo, Japan